Hyderabad:Natco Pharma Ltd has announced the launch of Ganciclovir said to be one of the latest generation drugs used in the treatment and prevention of cytomegalovirus. The drug was launched in 250 mg capsules and 500 ml injection forms.
In a statement the company said cytomegalovirus retinitis is a potential threat in immuno-compromised and AIDS patients, patients undergoing chemotherapy and recipients of organ transplants. In these cases, cytomegalovirus could lead to irreparable blindness, the company said.
According to the company, Ganciclovir, on its intake, converts itself to a triphosphate and effectively inhibits DNA polymerases and consequently its replication. The drug would effectively combat the eyesight threatening infection.